Correlation between susceptibility and BRO type enzyme of Moraxella catarrhalis strains

International Journal of Antimicrobial Agents

Volumn 22, Issue 5, 2003, Pages 532-536

  Kadry, Ashraf A ^a   Fouda, Soliman I ^a   Elkhizzi, Noura A ^b   Shibl, Atef M ^a,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Conjugation; Moraxella catarrhalis; Susceptibility; Lactamase characterization

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL ENZYME; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFALOTIN; CEFOPERAZONE; CEFOXITIN; CEFUROXIME; CEPHEM DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CORRELATION ANALYSIS; ENZYME ACTIVITY; ISOELECTRIC FOCUSING; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING TEST;

EID: 0242290073     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00158-4     Document Type: Article

References (23)

1. Morgan M.G., Mckenzie H., Enright M.C., Bain M., Emmanuel F.X.S. Use of molecular methods to characterize M. catarrhalis strains in a suspected outbreak of nosocomial infection. Eur. J. Clin. Microbiol. Infect. Dis. 11:1992;305-312.
2. Karalus R., Campagnari A. M. catarrhalis: a review of an important human mucosal pathogen. Microbes Infect. 2:2000;547-559.
3. Wallace R.J., Steingrube V.A., Nash D.R., et al. BRO β-lactamases of B. catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob. Agents Chemother. 33:1989;1845-1854.
4. Percival A., Corkill J.E., Rowlands J., Sykes R.B. Pathogenicity of and β-lactamase production by B. catarrhalis. Lancet. 3:1977;1175.
5. McGregor K., Chang B.J., Mee B.J., Riley T.V. M. catarrhalis: clinical significance, antimicrobial susceptibility and BRO β-lactamases. Eur. J. Clin. Microbiol. Infect. Dis. 17:1998;219-234.
6. Singh S., Cisera K.M., Turnidge J.D., Russell E.G. Selection of optimum laboratory tests for the identification of M. catarrhalis. Pathology. 29:1997;206-208.
7. VanHare G.F., Shurin P.A., Marchant C.D., et al. Acute otitis media caused by B. catarrhalis: biology and therapy. Rev. Infect. Dis. 9:1987;16-27.
8. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests. And Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Document M2-A7 and M7-A5. January 2000; Wayne, PA, USA.
9. Luman I., Wilson R.W., Wallace R.J., Nash D.R. Disk diffusion susceptibility of B. catarrhalis and relationship of β-lactam zone size to β-lactamase production. Antimicrob. Agents Chemother. 30:1986;774-776.
10. Fung C.P., Yeo S.F., Livermore D.M. Susceptibility of M. catarrhalis isolates to β-lactam antibiotics in relation to β-lactamase pattern. J. Antimicrob. Chemother. 33:1994;215-222.
11. Fung C.P., Yeo S.F., Livermore D.M. Extraction of β-lactamase from M. catarrhalis. J. Antimicrob. Chemother. 34:1994;183-184.
12. Plested S.J., Simpson I.N., James M. The detection of bacterial β-lactamases and their identification by analytical isoelectric focusing. Russell A.D., Quesnel L.B. Antibiotics: assessment of antimicrobial activity and resistance. 1983;111-126 Academic Press INC, New York, NY.
13. Eliasson I., Kamme C., Prellner K. β-Lactamase production in the upper respiratory tract flora. Eur. J. Clin. Microbiol. 5:1986;507-512.
14. Bryan L.E., Godfrey A.J. β-Lactam antibiotics. Lorian V. Antibiotics in laboratory medicine. 3rd ed. 1991;599-664 Williams and Wilkins, Baltimore, MD.
15. Kovatch A.L., Wald E.R., Michaels R.H. β-Lactamase-producing B. catarrhalis causing otitis media in children. J. Pediatrics. 102:1983;261-264.
16. Eliasson I., Kamme C., Vang M., Waley S.G. Characterization of cell-bound papain-soluble β-lactamases in BRO-1 and BRO-2 producing strains of M. catarrhalis and M. nonliquefaciens. Eur. J. Clin. Microbiol. Infect. Dis. 11:1992;313-321.
17. Kirven L.A., Thornsberry C. Transfer of β-lactamase genes of N. gonorrhoeae by conjugation. Antimicrob. Agents Chemother. 11:1977;1004-1006.
18. Verduin C.M., Hol C., Fleer A., Dijk H.V., Belkum A.V. M. catarrhalis: from emerging to established pathogen. Clin. Microbiol. Rev. 15:2002;125-144.
19. Doern G.V., Brueggemann A.B., Pierce G., Hogan T., Holley H.P., Rauch A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of M. catarrhalis in the USA in 1994 and 1995: results of a 30-center National surveillance study. Antimicrob. Agents Chemother. 40:1996;2884-2886.
20. Eliasson I., Kamme C. Characterization of the plasmid-mediated β-lactamase in B. catarrhalis, with special reference to substrate affinity. J. Antimicrob. Chemother. 15:1985;139-149.
21. Felmingham D., Gruneberg R.N. The Alexander project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. 45:2000;191-203.
22. Powell M., McVey D., Kassim M.H., Chen H.Y., Williams J.D. Antimicrobial susceptibility of S. pneumoniae, H. influenzae and B. catarrhalis isolated in the UK from sputa. J. Antimicrob. Chemother. 28:1991;249-259.
23. Kamme C., Eliasson I., Knutsen B.K., Vang M. Plasmid-mediated β-lactamase in B. catarrhalis. Drugs. 31:(Suppl 3):1986;55-63.